This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.
Eligibility
Sex
ALL
Min age
19 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent.
* Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.
* Subjects who present with at least one subjective symptom requiring medical treatment
* Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.
Exclusion Criteria:
* Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.
* Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.
Primary outcome measure(s)
The proportion of subjects with improvement in subjective symptoms — 2 weeks(up to 4 weeks) The proportion of subjects with improvement in subjective symptoms at Week 2 (up to Week 4) compared to baseline.
Trial sites (1)
Facility
City
Region
Status
Masong Kim Internal Medicine Clinic
Seoul
South Korea
Recruiting
More Daewoong Pharmaceutical Co. LTD. trials in South Korea
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.